FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

Bibliography

• ADACHI K, KOHARA T, NAKAO N, ARITA M, CHIBA K, MISHINA Z: Design, synthesis and structure-activity relationships of 2-substituted 2-amino-1,3-propandiols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. (1995) 5:853-856.
   Web of Science ®Google Scholar
• CHEN JK, LANE WS, SCHREIBER SL: The identification of myriocin-binding proteins. Chem. Biol. (1999) 6:221-235.
   PubMed Web of Science ®Google Scholar
• CHIBA K, YANAGAWA Y, MASUBUCHI Y et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. (1998) 160:5037-5044.
   PubMed Web of Science ®Google Scholar
• WATTENBERG BW, PITSON SM, RABEN DM: The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J. Lipid Res. (2006) 47:1128-1139.
   PubMed Web of Science ®Google Scholar
• SCHWAB SR, PEREIRA JP, MATLOUBIAN M, XU Y, HUANG Y, CYSTER JG: Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 309:1735-1739.
   PubMed Web of Science ®Google Scholar
• SPIEGEL S, CUVILLIER O, EDSALL LC et al.: Sphingosine-1-phosphate in cell growth and cell death. Ann. NY Acad. Sci. (1998) 845:11-18.
   PubMed Web of Science ®Google Scholar
• SPIEGEL S, MILSTIEN S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. (2003) 4:397-407.
   PubMed Web of Science ®Google Scholar
• ALLENDE ML, YAMASHITA T, PROIA RL: G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood (2003) 102:3665-3667.
   PubMed Web of Science ®Google Scholar
• MIZUGISHI K, YAMASHITA T, OLIVERA A, MILLER GF, SPIEGEL S, PROIA RL: Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol. (2005) 25:11113-11121.
   PubMed Web of Science ®Google Scholar
• HLA T: Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. (2004) 15:513-520.
   PubMed Web of Science ®Google Scholar
• PYNE S, PYNE NJ: Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochim. Biophys. Acta (2002) 1582:121-131.
   PubMed Web of Science ®Google Scholar
• BAUMRUKER T, BORNANCIN F, BILLICH A: The role of sphingosine and ceramide kinases in inflammatory responses. Immunol. Lett. (2005) 96:175-185.
   PubMed Web of Science ®Google Scholar
• GOETZL EJ, WANG W, MCGIFFERT C, HUANG MC, GRALER MH: Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J. Cell Biochem. (2004) 92:1104-1114.
   PubMed Web of Science ®Google Scholar
• THEILMEIER G, SCHMIDT C, HERRMANN J et al.: High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation (2006) 114:1403-1409.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, DAVIS MD, HEISE CE et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. (2002) 277:21453-21457.
   PubMed Web of Science ®Google Scholar
• MANDALA S, HAJDU R, BERGSTROM J et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296:346-349.
   PubMed Web of Science ®Google Scholar
• BILLICH A, BORNANCIN F, DEVAY P, MECHTCHERIAKOVA D, URTZ N, BAUMRUKER T: Phosphorylation of the imunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. (2003) 278:47408-47415.
   PubMed Web of Science ®Google Scholar
• ZEMANN B, KINZEL B, MULLER M et al.: Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood (2006) 107:1454-1458.
   PubMed Web of Science ®Google Scholar
• CHUN J, ROSEN H: Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. (2006) 12:161-171.
   PubMed Web of Science ®Google Scholar
• GRAELER M, GOETZL EJ: Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. (2002) 16:1874-1878.
   PubMed Web of Science ®Google Scholar
• MATLOUBIAN M, LO CG, CINAMON G et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 427:355-360.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4:1019-1025.
   PubMed Web of Science ®Google Scholar
• SINGER II, TIAN M, WICKHAM LA et al.: Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol. (2005) 175:7151-7161.
   PubMed Web of Science ®Google Scholar
• MCVERRY BJ, GARCIA JG: In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. (2005) 17:131-139.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, BAUMRUKER T: Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr. Opin. Pharmacol. (2006) 6:244-250.
   PubMed Web of Science ®Google Scholar
• SHIOW LR, ROSEN DB, BRDICKOVA N et al.: CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 440:540-544.
   PubMed Web of Science ®Google Scholar
• ROSEN H, GOETZL EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. (2005) 5:560-570.
   PubMed Web of Science ®Google Scholar
• PENG X, HASSOUN PM, SAMMANI S et al.: Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. (2004) 169:1245-1251.
   PubMed Web of Science ®Google Scholar
• SANCHEZ T, ESTRADA-HERNANDEZ T, PAIK JH et al.: Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. (2003) 278:47281-47290.
   PubMed Web of Science ®Google Scholar
• SANNA MG, WANG SK, GONZALEZ-CABRERA PJ et al.: Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. (2006) 2:434-441.
   PubMed Web of Science ®Google Scholar
• SINGLETON PA, DUDEK SM, MA SF, GARCIA JG: Transactivation of sphingosine-1-phosphate receptors is essential for vascular barrier regulation: novel role for hyaluronan and CD44 receptor family. J. Biol. Chem. (2006) 281(45):34381-34393.
   PubMed Web of Science ®Google Scholar
• COLOMBAIONI L, GARCIA-GIL M: Sphingolipid metabolites in neural signalling and function. Brain Res. Brain Res. Rev. (2004) 46:328-355.
   PubMed Web of Science ®Google Scholar
• JAILLARD C, HARRISON S, STANKOFF B et al.: Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. (2005) 25:1459-1469.
   PubMed Web of Science ®Google Scholar
• MENO-TETANG GM, LI H, MIS S et al.: Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl) ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. (2006) 34:1480-1487.
   PubMed Web of Science ®Google Scholar
• FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305:70-77.
   PubMed Web of Science ®Google Scholar
• WEBB M, THAM CS, LIN FF et al.: Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. (2004) 153:108-121.
   PubMed Web of Science ®Google Scholar
• KATAOKA H, SUGAHARA K, SHIMANO K et al.: FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. (2005) 2:439-448.
   PubMed Web of Science ®Google Scholar
• RAUSCH M, HIESTAND P, FOSTER CA, BAUMANN DR, CANNET C, RUDIN M: Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging (2004) 20:16-24.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355:1124-1140.
   PubMed Web of Science ®Google Scholar
• MASSBERG S, VON ANDRIAN UH: Fingolimod and sphingosine-1-phosphate-modifiers of lymphocyte migration. N. Engl. J. Med. (2006) 355:1088-1091.
   PubMed Web of Science ®Google Scholar
• KOYRAKH L, LUJAN R, COLON J et al.: Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J. Neurosci. (2005) 25:11468-11478.
   PubMed Web of Science ®Google Scholar
• SANNA MG, LIAO J, JO E et al.: Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. (2004) 279:13839-13848.
   PubMed Web of Science ®Google Scholar
• FORREST M, SUN SY, HAJDU R et al.: Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. (2004) 309:758-768.
   PubMed Web of Science ®Google Scholar
• GUO J, MACDONELL KL, GILES WR: Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. (1999) 438:642-648.
   PubMed Web of Science ®Google Scholar
• BUNEMANN M, BRANDTS B, ZU HERINGDORF DM, VAN KOPPEN CJ, JAKOBS KH, POTT L: Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J. Physiol. (1995) 489:701-707.
   PubMed Web of Science ®Google Scholar
• JAN LY, JAN YN: Heartfelt crosstalk: desensitization of the GIRK current. Nat. Cell Biol. (2000) 2:E165-E167.
   Web of Science ®Google Scholar
• TOLLE M, LEVKAU B, KEUL P et al.: Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. (2005) 96:913-920.
   PubMed Web of Science ®Google Scholar
• KIMURA T, SATO K, MALCHINKHUU E et al.: High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1283-1288.
   PubMed Web of Science ®Google Scholar
• HWANG MW, MATSUMORI A, FURUKAWA Y et al.: FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation (1999) 100:1322-1329.
   PubMed Web of Science ®Google Scholar
• PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B, BRINKMANN V, HENGARTNER H, ZINKERNAGEL RM: FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. (2000) 164:5761-5770.
   PubMed Web of Science ®Google Scholar
• MASOPUST D, LEFRANCOIS L: CD8 T-cell memory: the other half of the story. Microbes Infect. (2003) 5:221-226.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, CHEN S, FENG L, PINSCHEWER D, NIKOLOVA Z, HOF R: FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant. Proc. (2001) 33:530-531.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21:49-52.
   PubMed Web of Science ®Google Scholar